Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Connie Liao"'
Autor:
Vivian Chua, Marlana Orloff, Jessica LF Teh, Takahito Sugase, Connie Liao, Timothy J Purwin, Bao Q Lam, Mizue Terai, Grazia Ambrosini, Richard D Carvajal, Gary Schwartz, Takami Sato, Andrew E Aplin
Publikováno v:
EMBO Molecular Medicine, Vol 11, Iss 2, Pp n/a-n/a (2019)
Abstract Alterations in transcriptional programs promote tumor development and progression and are targetable by bromodomain and extraterminal (BET) protein inhibitors. However, in a multi‐site clinical trial testing the novel BET inhibitor, PLX511
Externí odkaz:
https://doaj.org/article/ad9494b5987a443bb7fdef74004cf81b
Autor:
Chiu-Hsiang Connie Liao, Nilay Bakoglu, Emine Cesmecioglu, Matthew Hanna, Fresia Pareja, Hannah Y. Wen, Timothy M. D’Alfonso, Edi Brogi, Yukako Yagi, Dara S. Ross
Publikováno v:
Pathology and Oncology Research, Vol 30 (2024)
Human epidermal growth factor receptor 2 (HER2) gene amplification and subsequent protein overexpression is a strong prognostic and predictive biomarker in invasive breast carcinoma (IBC). ASCO/CAP recommended tests for HER2 assessment include immuno
Externí odkaz:
https://doaj.org/article/5ad66b7fe96047f1846f4c6e6e954da9
Supplementary Figures 1-5 from Metabolic Adaptations to MEK and CDK4/6 Cotargeting in Uveal Melanoma
Autor:
Andrew E. Aplin, Julio Aguirre-Ghiso, Michael A. Davies, Takami Sato, Nelisa Bechtel, Connie Liao, Usman Baqai, Prem Patel, Vivian Chua, Anna Han, Timothy J. Purwin, Jessica L.F. Teh
Supplemental Figure 1. CDK4/6i + MEKi treatment does not modulate proteins within the apoptotic signaling pathway. Supplemental Figure 2. Growth of UM001 xenografts treated with MEKi and/or CDK4/6i. Supplemental Figure 3. RNA-seq samples cluster base
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::85006f5b1b7ea2fe04bccacbd4f5ada8
https://doi.org/10.1158/1535-7163.22521028
https://doi.org/10.1158/1535-7163.22521028
Autor:
Andrew E. Aplin, Takami Sato, Michael A. Davies, Ken Kageyama, Mizue Terai, Timothy J. Purwin, Connie Liao, Vivian Chua, Hanyin Cheng
Supplemental Table 1: Patient characteristics and treatment history.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::88c8eff6353e333392a201e27a98f86c
https://doi.org/10.1158/1535-7163.22509588
https://doi.org/10.1158/1535-7163.22509588
Autor:
Andrew E. Aplin, Julio Aguirre-Ghiso, Michael A. Davies, Takami Sato, Nelisa Bechtel, Connie Liao, Usman Baqai, Prem Patel, Vivian Chua, Anna Han, Timothy J. Purwin, Jessica L.F. Teh
Supplemental Table 1. RNA Seq z-score values for genes significantly up- or downregulated in MEKi-R or CDK4/6i-T groups compared to controls, corresponding to figure 3A. Data are indexed to show which genes are significant for each comparison (BHFDR
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::010561c8e09e98e68d8256516c17c305
https://doi.org/10.1158/1535-7163.22521025.v1
https://doi.org/10.1158/1535-7163.22521025.v1
Autor:
Andrew E. Aplin, Takami Sato, Michael A. Davies, Ken Kageyama, Mizue Terai, Timothy J. Purwin, Connie Liao, Vivian Chua, Hanyin Cheng
Patients with metastatic uveal melanoma usually die within 1 year of diagnosis, emphasizing an urgent need to develop new treatment strategies. The liver is the most common site of metastasis. Mitogen-activated protein kinase kinase (MEK) inhibitors
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::13a73bcb3b678a5be53735d3d8802761
https://doi.org/10.1158/1535-7163.c.6539340
https://doi.org/10.1158/1535-7163.c.6539340
Autor:
Andrew E. Aplin, Julio Aguirre-Ghiso, Michael A. Davies, Takami Sato, Nelisa Bechtel, Connie Liao, Usman Baqai, Prem Patel, Vivian Chua, Anna Han, Timothy J. Purwin, Jessica L.F. Teh
Frequent GNAQ and GNA11 mutations in uveal melanoma hyperactivate the MEK–ERK signaling pathway, leading to aberrant regulation of cyclin-dependent kinases (CDK) and cell-cycle progression. MEK inhibitors (MEKi) alone show poor efficacy in uveal me
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8060e37103f45fc1d0c5ac98b19764a9
https://doi.org/10.1158/1535-7163.c.6542872
https://doi.org/10.1158/1535-7163.c.6542872
Autor:
Andrew E. Aplin, Takami Sato, Michael A. Davies, Ken Kageyama, Mizue Terai, Timothy J. Purwin, Connie Liao, Vivian Chua, Hanyin Cheng
Supplemental Figure 1 to 5 legends
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a3f985c5f9a93e27e735be8721a25aaf
https://doi.org/10.1158/1535-7163.22509591.v1
https://doi.org/10.1158/1535-7163.22509591.v1
Autor:
Andrew E. Aplin, Takami Sato, Michael A. Davies, Ken Kageyama, Mizue Terai, Timothy J. Purwin, Connie Liao, Vivian Chua, Hanyin Cheng
Supplemental Figure 1: HGF inhibits trametinib-induced apoptosis in UM cells; Supplemental Figure 2: Bim-EL or Bmf expression renders UM cells susceptible to apoptosis; Supplemental Figure 3: Human hepatic stellate cell (HHSteC) conditioned medium ac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d35f98f5233a13f129f1113febfd2f3
https://doi.org/10.1158/1535-7163.22509594
https://doi.org/10.1158/1535-7163.22509594
Autor:
Vivian Chua, Connie Liao, Timothy J. Purwin, Emily Hunter, Anna Han, J. William Harbour, Andrew E. Aplin, Nelisa Bechtel
Publikováno v:
Pigment Cell & Melanoma Research. 35:78-87
Metastatic uveal melanoma (UM) responds poorly to targeted therapies and immune checkpoint inhibitors. Loss of BRCA1-associated protein 1 (BAP1) via inactivating mutations in the BAP1 gene is associated with UM progression. Thus, molecular alteration